GlassScriptPhysician profile
Methee Srivatana
NPI 1962679068
$10,219.12
in general payments reported to CMS, 2019-2025
29 companies · $1,001 in 2025
The $1,001 reported for 2025 was more than what a typical Rheumatology provider received nationally (typical 2025 total: $894).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $5,014 · 2020: $820 · 2021: $132 · 2022: $828 · 2023: $1,306 · 2024: $1,119 · 2025: $1,001.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,426.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,425.93 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Horizon Therapeutics Plc | $2,445.00 | 2019-2023 | Krystexxa |
| Abbvie INC. | $1,842.24 | 2019-2025 | Rinvoq, Skyrizi |
| Amgen INC. | $1,354.19 | 2019-2025 | Enbrel, Otezla, Tavneos |
| Pfizer INC. | $695.81 | 2019-2025 | |
| Janssen Biotech, INC. | $611.91 | 2019-2025 | Tremfya |
| Novartis Pharmaceuticals Corporation | $570.27 | 2019-2025 | |
| Genentech USA, INC. | $412.20 | 2019-2025 | Actemra |
| Lilly USA, LLC | $401.58 | 2019-2025 | Taltz, Zepbound |
| Glaxosmithkline, LLC. | $336.54 | 2019-2025 | Benlysta |
| E.R. Squibb & Sons, L.L.C. | $286.95 | 2019-2025 | Orencia |
| Ucb, INC. | $254.55 | 2019-2025 | Cimzia, Bimzelx |
| Mallinckrodt Enterprises LLC | $212.46 | 2019 | |
| Astrazeneca Pharmaceuticals LP | $132.14 | 2021-2025 | Saphnelo |
| Alexion Pharmaceuticals, INC. | $78.40 | 2019-2025 | Strensiq |
| Mallinckrodt Hospital Products INC. | $72.75 | 2020-2022 |
Show all 29 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pacira Therapeutics, INC. | $63.42 | 2019 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $62.90 | 2020-2024 | Cyltezo, Ofev |
| Regeneron Healthcare Solutions, INC. | $59.56 | 2019 | |
| Genzyme Corporation | $56.68 | 2025 | |
| Medexus Pharma, INC. | $53.60 | 2019 | |
| Ani Pharmaceuticals, INC. | $51.52 | 2022-2023 | Purified Cortrophin Gel |
| Celgene Corporation | $40.03 | 2019 | |
| Actelion Pharmaceuticals US, INC. | $22.20 | 2022 | |
| Bioventus LLC | $21.17 | 2019 | |
| Radius Health, INC. | $20.35 | 2020 | |
| Aurinia Pharma U.S., INC. | $20.28 | 2022 | |
| Sandoz INC. | $14.58 | 2023 | Hyrimoz |
| Sobi, INC | $14.40 | 2023 | |
| Takeda Pharmaceuticals U.S.A., INC. | $11.44 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Methee Srivatana listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.